Payment overview · 2025
General Payments
$49.85
2 reported records · 2 companies
Healthcare provider profile · identity verified
Nolberto Sanchez, M.D.
Allopathic & Osteopathic Physicians|General Practice · MARIANNA, FL · NPI 1790970788
Verified facts
What the public records show
CMS Open Payments records show Nolberto Sanchez, M.D. received $49.85 in general payments during 2025 across 2 reported records.
SANOFI PASTEUR INC. accounted for 67.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $33.86 | 67.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 32.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.85 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $33.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 130 |
| Tramadol Hcl | Tramadol Hcl | 453 | 91 |
| Gabapentin | Gabapentin | 432 | 103 |
| Lisinopril | Lisinopril | 420 | 115 |
| Prednisone | Prednisone | 278 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 79 |
| Alprazolam | Alprazolam | 257 | 39 |
| Metformin Hcl | Metformin Hcl | 252 | 76 |
| Omeprazole | Omeprazole | 242 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 90 |
| Losartan Potassium | Losartan Potassium | 222 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 213 | 60 |
| Ibuprofen | Ibuprofen | 212 | 73 |
| Furosemide | Furosemide | 197 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 56 |
| Clonazepam | Clonazepam | 184 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 57 |
| Carvedilol | Carvedilol | 167 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 19 |
| Alendronate Sodium | Alendronate Sodium | 159 | 55 |
| Glipizide | Glipizide | 155 | 39 |
| Potassium Chloride | Potassium Chloride | 151 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 55 |
| Montelukast Sodium | Montelukast Sodium | 134 | 43 |
| Trazodone Hcl | Trazodone Hcl | 123 | 26 |
| Pregabalin | Pregabalin | 120 | 21 |
| Mirtazapine | Mirtazapine | 118 | 31 |
| Spironolactone | Spironolactone | 116 | 38 |
| Farxiga | Dapagliflozin Propanediol | 115 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 31 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 102 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 29 |
| Methocarbamol | Methocarbamol | 100 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 54 |
| Ezetimibe | Ezetimibe | 94 | 31 |
| Azithromycin | Azithromycin | 90 | 56 |
| Sertraline Hcl | Sertraline Hcl | 90 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 20 |
| Ondansetron Odt | Ondansetron | 87 | 28 |
| Promethazine Hcl | Promethazine Hcl | 86 | 28 |
| Clonidine Hcl | Clonidine Hcl | 84 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 49 |
| Famotidine | Famotidine | 74 | 24 |
| Allopurinol | Allopurinol | 72 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | 11 |
| Januvia | Sitagliptin Phosphate | 69 | 22 |
| Pentoxifylline | Pentoxifylline | 67 | 21 |
| Eliquis | Apixaban | 66 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Amoxicillin | Amoxicillin | 64 | 50 |
| Carisoprodol | Carisoprodol | 60 | 14 |
| Simvastatin | Simvastatin | 60 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 25 |
| Finasteride | Finasteride | 58 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 12 |
| Megestrol Acetate | Megestrol Acetate | 56 | 17 |
| Meloxicam | Meloxicam | 56 | 21 |
| Linzess | Linaclotide | 54 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 24 |
| Glipizide Er | Glipizide | 52 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 13 |
| Midodrine Hcl | Midodrine Hcl | 50 | 15 |
| Sucralfate | Sucralfate | 50 | 36 |
| Colchicine | Colchicine | 48 | 30 |
| Baclofen | Baclofen | 46 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 33 |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 21 |
| Methotrexate | Methotrexate Sodium | 42 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 42 | suppressed |
| Ozempic | Semaglutide | 42 | 15 |
| Jardiance | Empagliflozin | 41 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 40 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | 19 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 38 | suppressed |
| Klor-Con 10 | Potassium Chloride | 38 | 11 |
| Azelastine Hcl | Azelastine Hcl | 37 | 17 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 14 |
| Donepezil Hcl | Donepezil Hcl | 36 | 13 |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 14 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 19 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Klor-Con 8 | Potassium Chloride | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Kerendia | Finerenone | 20 | 11 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 15 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.85 · 2 records | SANOFI PASTEUR INC. | BEYFORTUS, FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error